Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
Kim N ChiAlan BarnicleCaroline SibillaZhongwu LaiClaire CorcoranJ Carl BarrettCarrie A AdelmanPing QiuAshley D EasterSimon DeardenGeoffrey R OxnardArchana M AgarwalArun A AzadJohann S de BonoJoaquin MateoDavid OlmosAntoine Thiery-VuilleminElizabeth A HarringtonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
We demonstrate that ctDNA can greatly complement tissue testing in identifying patients with mCRPC and BRCA or ATM alterations who are potentially suitable for receiving targeted PARP inhibitor treatments, particularly patients with no or insufficient tissue for genomic analyses.